CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium*

In this phase II study, no responses were seen with pemigatinib in the 14 enrolled patients with previously treated mCRC with FGF/FGFR gene mutations or amplifications.

Analysis of the MOUNTAINEER trial showed high concordance in HER2 scoring in mCRC using breast and gastric HER2 testing algorithms.

With 29 months of follow-up, both nivolumab + chemotherapy and nivolumab + ipilimumab continued to demonstrate clinically meaningful OS benefit compared with chemotherapy alone in previously untreated patients with advanced esophageal SCC.

With 36 months of follow-up, the addition of nivolumab to chemotherapy continued to demonstrate PFS and OS benefits vs chemotherapy alone in previously untreated patients with advanced gastric/GEJ cancer and esophageal adenocarcinoma.

Results from the phase III SUNLIGHT trial showed that adding bevacizumab to third-line TAS-102 significantly improved OS and PFS in refractory mCRC.

Pembrolizumab plus lenvatinib and chemotherapy showed a manageable safety profile and preliminary antitumor activity in patients with advanced gastroesophageal cancers.

Addition of zolbetuximab to mFOLFOX6 improved PFS and OS compared with mFOLFOX alone for previously untreated patients with advanced CLDN18.2+/HER2- gastric/gastroesophageal junction adenocarcinoma.

The phase III SWOG 1815 trial showed that adding nab-paclitaxel to first-line gemcitabine/cisplatin did not significantly prolong OS or PFS and was associated with increased severe hematologic toxicity in advanced biliary tract cancers.

First-line therapy with NALIRIFOX statistically significantly improved OS and PFS vs gemcitabine plus nab-paclitaxel for metastatic PDAC.